News >

Pegram Discusses Future of Biosimilars in Oncology

Brandon Scalea
Published: Monday, Nov 19, 2018

Mark Pegram, MD

Mark Pegram, MD
It is only a matter of time before more oncologic biosimilars become available as patent expirations are upcoming for several reference products in the field, said Mark D. Pegram, MD.

, Pegram highlighted the gradually evolving landscape of biosimilars and provided insight on how they can shape the US market.

OncLive: What future impact will biosimilars have in the oncology space?

Pegram: Biosimilar drug development in oncology is a very fast-paced and exciting field. An opportunity presents itself because of patent expirations that are upcoming in the next couple of years for several biologics currently on the market. As those patents expire, that creates a framework for more biosimilars to be used commercially. Historically, non-oncology biosimilar products tend to be cheaper; consequentially, this opens the doors to new markets on a global scale.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication
x